Terms: = Lymphoma AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716
226 results:
1. [Pathogenesis and Targeted Treatment Progress of Splenomegaly in Primary Myelofibrosis--Review].
Chen ZW; Wang SX; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):308-312. PubMed ID: 38387940
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and Safety in Early application of Ruxolinitib for high-risk: Acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation.
Cheng Q; Tang Y; Liu F; Li X; Fang D
Transpl Immunol; 2024 Apr; 83():101978. PubMed ID: 38302005
[TBL] [Abstract] [Full Text] [Related]
3. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma.
Chiba M; Shimono J; Suto K; Ishio T; Endo T; Goto H; Hasegawa H; Maeda M; Teshima T; Yang Y; Nakagawa M
Blood; 2024 Apr; 143(14):1379-1390. PubMed ID: 38142436
[TBL] [Abstract] [Full Text] [Related]
4. Golidocitinib, a selective jak1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Song Y; Malpica L; Cai Q; Zhao W; Zhou K; Wu J; Zhang H; Mehta-Shah N; Ding K; Liu Y; Li Z; Zhang L; Zheng M; Jin J; Yang H; Shuang Y; Yoon DH; Gao S; Li W; Zhai Z; Zou L; Xi Y; Koh Y; Li F; Prince M; Zhou H; Lin L; Liu H; Allen P; Roncolato F; Yang Z; Kim WS; Zhu J
Lancet Oncol; 2024 Jan; 25(1):117-125. PubMed ID: 38092009
[TBL] [Abstract] [Full Text] [Related]
5. Dependence of peripheral T-cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach.
Le K; Vollenweider J; Han J; Staudinger N; Stenson M; Bayraktar L; Wellik LE; Maurer MJ; McPhail ED; Witzig TE; Gupta M
Hematol Oncol; 2024 Jan; 42(1):e3233. PubMed ID: 37876297
[TBL] [Abstract] [Full Text] [Related]
6. XBP1 promotes NRAS
Salimi A; Schemionek-Reinders M; Huber M; Vieri M; Patterson JB; Alten J; Brümmendorf TH; Kharabi Masouleh B; Appelmann I
J Cell Mol Med; 2023 Nov; 27(21):3363-3377. PubMed ID: 37753803
[TBL] [Abstract] [Full Text] [Related]
7. The JAK3
Lahera A; Vela-Martín L; Fernández-Navarro P; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
Mol Carcinog; 2024 Jan; 63(1):5-10. PubMed ID: 37712558
[TBL] [Abstract] [Full Text] [Related]
8. Phase I dose escalation and expansion study of golidocitinib, a highly selective jak1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas.
Song Y; Yoon DH; Yang H; Cao J; Ji D; Koh Y; Jing H; Eom H; Kwak J; Lee W; Lee J; Shin H; Jin J; Wang M; Yang Z; Kim WS; Zhu J
Ann Oncol; 2023 Nov; 34(11):1055-1063. PubMed ID: 37673210
[TBL] [Abstract] [Full Text] [Related]
9. Higher 13-Gene-Estimated TMB Detected from Plasma ctDNA is Associated with Worse Outcome for T-Cell lymphoma Patients.
Chen C; Huang L; Chen Z; Ou Q; Liu S; Jiang X; Chen F; Wei X; Guo H; Shao Y; Zeng C; Li Y; Li W
Adv Biol (Weinh); 2023 Dec; 7(12):e2300042. PubMed ID: 37658484
[TBL] [Abstract] [Full Text] [Related]
10. Characteristics of Molecular Genetic Mutations and Their Correlation with Prognosis in Adolescent and Adult Patients with Acute Lymphoblastic Leukemia.
Sun X; Liu X; Li Y; Shi X; Li Y; Tan R; Jiang Y; Sui X; Ge X; Xu H; Wang X; Fang X
Oncology; 2024; 102(1):85-98. PubMed ID: 37437551
[TBL] [Abstract] [Full Text] [Related]
11. Autosomal Dominant STAT6 Gain of Function Causes Severe Atopy Associated with lymphoma.
Minskaia E; Maimaris J; Jenkins P; Albuquerque AS; Hong Y; Eleftheriou D; Gilmour KC; Grace R; Moreira F; Grimbacher B; ; Morris EC; Burns SO
J Clin Immunol; 2023 Oct; 43(7):1611-1622. PubMed ID: 37316763
[TBL] [Abstract] [Full Text] [Related]
12. Rare lymphomas: Getting "a Bit Ahead".
Cancer Discov; 2023 Aug; 13(8):OF4. PubMed ID: 37294133
[TBL] [Abstract] [Full Text] [Related]
13. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
[TBL] [Abstract] [Full Text] [Related]
14. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
Zhou C; Yang X; Yang B; Yan G; Dong X; Ding Y; Fan W; Li L; Yang D; Fang H; Ji C; Cheng H; Zhang S; Goh AH; Liu R; Gu X; Weng Z; Foley P; Sinclair R; Zhang J
J Am Acad Dermatol; 2023 Nov; 89(5):911-919. PubMed ID: 37019385
[TBL] [Abstract] [Full Text] [Related]
15. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms.
Jaeger A; Gambheer SMM; Sun X; Chernyakov D; Skorobohatko O; Mack T; Kissel S; Pfeifer D; Zeiser R; Fisch P; Andrieux G; Bräuer-Hartmann D; Bauer M; Schulze S; Follo M; Boerries M; von Bubnoff N; Miething C; Hidalgo JV; Klein C; Weber T; Wickenhauser C; Binder M; Dierks C
Blood; 2023 Jun; 141(23):2824-2840. PubMed ID: 36696631
[TBL] [Abstract] [Full Text] [Related]
16. SOHO State of the Art Updates and Next Questions | Polycythemia Vera: Is It Time to Rethink Treatment?
Mora B; Passamonti F
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):79-85. PubMed ID: 36566109
[TBL] [Abstract] [Full Text] [Related]
17. Molecular and clinical diversity in primary central nervous system lymphoma.
Hernández-Verdin I; Kirasic E; Wienand K; Mokhtari K; Eimer S; Loiseau H; Rousseau A; Paillassa J; Ahle G; Lerintiu F; Uro-Coste E; Oberic L; Figarella-Branger D; Chinot O; Gauchotte G; Taillandier L; Marolleau JP; Polivka M; Adam C; Ursu R; Schmitt A; Barillot N; Nichelli L; Lozano-Sánchez F; Ibañez-Juliá MJ; Peyre M; Mathon B; Abada Y; Charlotte F; Davi F; Stewart C; de Reyniès A; Choquet S; Soussain C; Houillier C; Chapuy B; Hoang-Xuan K; Alentorn A
Ann Oncol; 2023 Feb; 34(2):186-199. PubMed ID: 36402300
[TBL] [Abstract] [Full Text] [Related]
18. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
Stein BL
Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
[TBL] [Abstract] [Full Text] [Related]
19. JAK: Not Just Another Kinase.
Agashe RP; Lippman SM; Kurzrock R
Mol Cancer Ther; 2022 Dec; 21(12):1757-1764. PubMed ID: 36252553
[TBL] [Abstract] [Full Text] [Related]
20. IFN-γ enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway.
Shao X; Meng X; Yang H; Wang X; Qin L; Shen G; Xi X; Zhao H; Macip S; Chen Y
Leuk Lymphoma; 2023 Jan; 64(1):71-78. PubMed ID: 36222521
[TBL] [Abstract] [Full Text] [Related]
[Next]
